Revenue - The Company reported no revenue for the three months ended September 30, 2025 and 2024[114] Operating Expenses - Operating expenses decreased to $1,853,304 for the three months ended September 30, 2025, down from $2,870,932 in the same period of 2024, a reduction of approximately 35.4%[115] - For the nine months ended September 30, 2025, operating expenses increased to $5,333,124 from $3,688,584 in the same period of 2024, an increase of approximately 44.6%[118] Net Loss - The net loss for the three months ended September 30, 2025 was $2,895,585, compared to a net loss of $2,959,426 for the same period in 2024, reflecting a decrease of about 2.2%[116] - The net loss for the nine months ended September 30, 2025 was $9,222,798, compared to $4,083,109 for the same period in 2024, representing an increase of approximately 126.4%[119] Cash Flow - Net cash used in operating activities for the nine months ended September 30, 2025 was $4,610,390, compared to $2,002,358 for the same period in 2024, an increase of approximately 130.5%[121] - The Company had cash and cash equivalents of $7,348,034 as of September 30, 2025, with an accumulated deficit of approximately $19.8 million[127] - Net cash provided by financing activities for the nine months ended September 30, 2025 was $11,894,683, significantly higher than $2,173,942 for the same period in 2024[123][124] Future Outlook - The Company expects to continue incurring significant professional costs to remain publicly traded and requires additional working capital funding to execute its business plans[125][127] - The Company has no off-balance sheet arrangements as of September 30, 2025[128]
Klotho Neurosciences, Inc.(KLTO) - 2025 Q3 - Quarterly Report